These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 36893587)

  • 1. Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer.
    Hung CL; Liu HH; Fu CW; Yeh HH; Hu TL; Kuo ZK; Lin YC; Jhang MR; Hwang CS; Hsu HC; Kung HJ; Wang LY
    EBioMedicine; 2023 Apr; 90():104500. PubMed ID: 36893587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer.
    Yi Q; Liu W; Seo JH; Su J; Alaoui-Jamali MA; Luo J; Lin R; Wu JH
    Mol Cancer Ther; 2023 May; 22(5):570-582. PubMed ID: 37139712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted peptide PROTAC for Prostate Cancer Therapy.
    Ma B; Fan Y; Zhang D; Wei Y; Jian Y; Liu D; Wang Z; Gao Y; Ma J; Chen Y; Xu S; Li L
    Adv Sci (Weinh); 2022 Oct; 9(28):e2201859. PubMed ID: 35971165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
    Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
    Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of
    Zhang B; Liu C; Yang Z; Zhang S; Hu X; Li B; Mao M; Wang X; Li Z; Ma S; Zhang S; Qin C
    J Med Chem; 2023 Aug; 66(16):11158-11186. PubMed ID: 37556600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
    Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
    Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM
    Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
    Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy.
    Lee GT; Nagaya N; Desantis J; Madura K; Sabaawy HE; Kim WJ; Vaz RJ; Cruciani G; Kim IY
    Mol Cancer Ther; 2021 Mar; 20(3):490-499. PubMed ID: 33277442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
    Yi Q; Han X; Yu HG; Chen HY; Qiu D; Su J; Lin R; Batist G; Wu JH
    Oncogene; 2024 May; 43(20):1522-1533. PubMed ID: 38532114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy.
    Zhang D; Ma B; Liu D; Wu W; Zhou T; Gao Y; Yang C; Jian Y; Fan Y; Qian Y; Ma J; Gao Y; Chen Y; Xu S; Li L
    EBioMedicine; 2024 Jul; 105():105212. PubMed ID: 38954976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
    Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
    Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer.
    Zhang Y; Ming A; Wang J; Chen W; Fang Z
    Pharmacol Res; 2024 Jul; 205():107234. PubMed ID: 38815882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
    Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
    Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
    [No Abstract]   [Full Text] [Related]  

  • 20. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.